NASDAQ$TVRD
Tvardi Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
TVRD Q2 2024 — $2.7M revenue
The Company’s condensed consolidated financial statements include the results of the financial operations of Cara Therapeutics, Inc. Tvardi Therapeutics Inc reported Q2 2024 results. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $2.7M.
- Filed on Form 10-Q (accession 0001558370-24-012231).
Headline financials
Revenue & EPS history
Tvardi Therapeutics · Revenue · Quarterly
$991K
Revenue by segment
Tvardi Therapeutics · $8.1M total across 1 segment · Q1 2020
- Collaboration Revenue$8.1M—100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+1.4%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+0.6%
Avg return
30 days after
50%
24 / 48 earnings
Positive
+42.3%
Q3 2016
Best reaction
-34.9%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2024 | +5.0% | -2.5% | +11.3% | |
| Q3 2024 | -4.1% | -7.1% | -19.1% | |
| Q2 2024 | -3.9% | -4.1% | -22.2% | |
| Q1 2024 | +1.0% | +4.7% | -5.0% | |
| Q4 2023 | -4.2% | +3.3% | -4.5% | |
| Q3 2023 | +4.3% | +4.8% | +14.3% | |
| Q2 2023 | -6.1% | -1.9% | -31.0% | |
| Q1 2023 | +11.2% | -5.2% | -16.0% | |
| Q4 2022 | -34.9% | -41.1% | -54.2% | |
| Q3 2022 | +3.6% | +20.8% | +35.4% | |
| Q2 2022 | +4.8% | +2.1% | -2.8% | |
| Q1 2022 | +14.7% | +4.5% | +9.8% | |
| Q4 2021 | +11.2% | +3.2% | +17.2% | |
| Q3 2021 | +1.4% | -9.2% | -28.5% | |
| Q2 2021 | +1.6% | +8.4% | +21.6% | |
| Q1 2021 | +3.7% | +5.1% | +10.1% | |
| Q4 2020 | -7.4% | -4.6% | +1.6% | |
| Q3 2020 | +7.7% | +10.5% | +6.4% | |
| Q2 2020 | +2.8% | -3.9% | -8.0% | |
| Q1 2020 | +6.8% | +6.1% | +16.1% | |
| Q4 2019 | -5.2% | -6.4% | -20.6% | |
| Q3 2019 | -4.8% | +3.9% | -20.9% | |
| Q2 2019 | +8.2% | +3.6% | +6.0% | |
| Q1 2019 | -5.1% | -6.7% | -0.4% | |
| Q4 2018 | +13.7% | +7.2% | +13.7% | |
| Q3 2018 | +0.8% | +0.6% | -12.5% | |
| Q2 2018 | +6.0% | +9.6% | +11.3% | |
| Q1 2018 | -3.4% | +1.5% | +30.4% | |
| Q4 2017 | -9.2% | -15.0% | -10.1% | |
| Q3 2017 | +1.2% | +2.2% | +4.9% | |
| Q2 2017 | +22.9% | +8.1% | +4.5% | |
| Q1 2017 | -7.7% | -4.6% | +10.3% | |
| Q4 2016 | -12.3% | -10.9% | +4.1% | |
| Q3 2016 | +42.3% | +58.9% | +61.3% | |
| Q2 2016 | -1.5% | -0.7% | -12.5% | |
| Q1 2016 | -4.3% | — | — | |
| Q4 2015 | -3.8% | — | — | |
| Q3 2015 | +11.9% | — | — | |
| Q2 2015 | +4.0% | — | — | |
| Q1 2015 | -1.6% | — | — | |
| Q4 2014 | +10.2% | — | — | |
| Q3 2013 | -2.1% | — | — | |
| Q3 2014 | -2.1% | — | — | |
| Q2 2014 | -1.8% | — | — | |
| Q2 2013 | -1.8% | — | — | |
| Q1 2013 | -1.7% | — | — | |
| Q1 2014 | -1.7% | — | — | |
| Q4 2013 | -2.7% | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro